Home / Analysis kits / MSI OncoKitDx

MSI OncoKitDx

Description

Detection of microsatellite instability by capillary electrophoresis

Format

48 rxn

Technology

Fragment Analysis

Reference

IMG-314

Compatible equipment

3730xl DNA Analyzer (ThermoFisher Scientific)

Kit Health in Code
Request kit
  • Qualitative analysis that evaluates eight markers: BAT25, BAT26, D2S123, D5S346, and D17S250, recommended by the National Cancer Institute (NCI) since 1997 and known as the Bethesda panel; and BAT40, NR21 and NR22, whose sensitivity and informativeness in different tissues has been demonstrated in the scientific literature.
  • The markers D2S123, D5S346 and D17S250, highly polymorphic, when they do not suffer from instability, allow the assessment of concordance between pathological and normal tissue, ensuring sample traceability.
  • Amplification range of 90-200 bp.
  • Includes a genomic DNA control at the optimal amplification concentration, containing normal alleles for the markers amplified in the kit.
  • For research use only, intended for professionals working in molecular biology.

MSI OncoKitDx employs oligonucleotides labeled with different fluorophores in an assay that uses standard PCR technique to amplify regions of interest and capillary electrophoresis to detect potential instability of any of the eight microsatellite regions included in this analysis.

  • Amount of DNA: 10 ng
  • Type of sample: paraffin or fresh tissue (tumor), peripheral blood (germinal)
  • Number of reactions per sample: 1
  • Number of targets: 1
  • Manual work time: 30 minutes
  • Duration of the PCR program: 2 hours
  • Compatible thermal cyclers: any conventional thermal cycler
  • Sequencing with polymers compatible with FAMTM, VIC® and NEDTM
MSI OncoKitDx: MSDS (english)
MSI OncoKitDx: Instructions for use
Analysis certificate

MSI OncoKitDx

Fill in the form to request this kit.

Call us at +34 963 212 340

Or write to us at info@healthincode.com

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Consentimiento*